Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session



  • Revelation Biosciences, Inc. REVB jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.
  • NeuroSense Therapeutics Ltd. NRSN shares jumped 44.7% to $3.9650 after the company announced results from a biomarker study to evaluate the potential of CogniC, a combination drug for Alzheimer's disease (AD).
  • Rapid Micro Biosystems, Inc. RPID gained 35.5% to $4.31 after Kennedy Lewis Investment Management LLC announced an offer to acquire Rapid Micro Biosystems.
  • Color Star Technology Co., Ltd. CSCW rose 33.5% to $0.1753.
  • Dermata Therapeutics, Inc. DRMA gained 25% to $0.68.
  • Ipsidy Inc. AUID surged 24.7% to $1.87.
  • 374Water, Inc. SCWO rose 20.1% to $3.3877.
  • Tuniu Corporation TOUR jumped 20% to $0.9999.
  • HeartCore Enterprises, Inc. HTCR gained 20% to $2.6334.
  • IperionX Limited IPX surged 17.4% to $6.34.
  • Revlon, Inc. REV surged 16.6% to $5.34 on continued post-bankruptcy volatility. The stock has been mentioned on social media as a potential short squeeze candidate.
  • Aspen Aerogels, Inc. ASPN shares gained 16.6% to $9.83 after the company announced its decision not to proceed with concurrent public offerings of common stock and green convertible senior notes due 2027.
  • Franklin Covey Co. FC jumped 13.5% to $43.16 after reporting Q3 results.
  • AEye, Inc. LIDR gained 12.7% to $1.9850.
  • Kewaunee Scientific Corporation KEQU jumped 12.3% to $15.45.
  • Remark Holdings, Inc. MARK jumped 9.5% to $0.4340.
  • Northern Lights Acquisition Corp. NLIT gained 9.2% to $10.41.
  • Applied Therapeutics, Inc. APLT rose 7.8% to $0.9487. Applied Therapeutics recently announced a $30 million public offering of common stock and warrants.
  • ThermoGenesis Holdings, Inc. THMO rose 7.1% to $0.2998.




  • Cryptyde Inc. TYDE fell 64.4% to $2.24.
  • Akerna Corp. KERN fell 51.4% to $0.1429 after the company announced pricing of a $10 million public offering.
  • Renalytix Plc RNLX dipped 40.5% to $2.3550.
  • Enjoy Technology, Inc. ENJY dipped 38% to $0.1786.
  • Angion Biomedica Corp. ANGN fell 36.8% to $1.0801. Angion Biomedica discontinued the JUNIPER Phase 2 trial of ANG-3070, an oral tyrosine kinase inhibitor, in primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis and immunoglobulin A nephropathy.
  • COMSovereign Holding Corp. COMS shares fell 33.8% to $0.1642 after jumping over 60% on Wednesday.
  • Allena Pharmaceuticals, Inc. ALNA fell 33.7% to $0.1689. Allena Pharmaceuticals shares jumped 114% on Wednesday after the company announced it has terminated its previously announced at-the-market offering.
  • Duck Creek Technologies, Inc. DCT fell 26.5% to $13.53 after the company issued Q4 and FY22 sales guidance below estimates. The company also reported a year-over-year decrease in Q3 EPS results.
  • Biophytis S.A. BPTS fell 25% to $1.05.
  • Kalera Public Limited Company KAL dropped 24.9% to $6.50.
  • Endo International plc ENDP fell 24.4% to $0.3949.
  • Cyclacel Pharmaceuticals, Inc. CYCC dipped 23.7% to $1.13.
  • Lytus Technologies Holdings PTV. Ltd. LYT fell 22.9% to $4.20.
  • SMART Global Holdings, Inc. SGH shares dipped 22.3% to $15.75. SMART Global reported upbeat results for its third quarter, but issued weak forecast for the current quarter. The company also agreed to acquire Stratus Technologies for $225 million in cash at closing and an earn-out payment of up to $50 million.
  • Brickell Biotech, Inc. BBI fell 21.6% to $0.1349 after jumping around 48% on Wednesday.
  • Aditxt, Inc. ADTX dropped 21.5% to $0.1570.
  • Grove Collaborative Holdings, Inc. GROV fell 21.1% to $4.82.
  • Advanced Human Imaging Limited AHI fell 20.9% to $0.56.
  • Aeterna Zentaris Inc. AEZS fell 19.7% to $0.2074.
  • Borr Drilling Limited BORR dropped 19.1% to $4.39.
  • Exicure, Inc. XCUR fell 19% to $2.2450 following effect of 1:30 reverse stock split.
  • 9 Meters Biopharma, Inc. NMTR declined 19% to $0.2695. 9 Meters Biopharma disclosed preliminary results from Phase 2 study of vurolenatide in short bowel syndrome.
  • Canopy Growth Corporation CGC dropped 18.7% to $2.8450 after the company announced it entered into exchange agreements with holders of approximately $198 million of convertible notes. Also, Piper Sandler lowered its price target on the stock from $4 to $3.
  • Agile Therapeutics, Inc. AGRX fell 18.2% to $1.26 after the company filed for an offering of up to approximately 15.75 million shares
  • Hyperfine, Inc. HYPR shares fell 17.6% to $2.2250. Hyperfine appointed Scott Huennekens as Interim President & CEO.
  • The9 Limited NCTY fell 16.2% to $1.7861.
  • Codiak BioSciences, Inc. CDAK declined 16.1% to $3.0555. Codiak BioSciences announced platform-validating clinical data from Phase 1 trials of exoSTING and exoIL-12, and it plans to advance both candidates into Phase 2 trials.
  • Aethlon Medical, Inc. AEMD fell 15.4% to $1.1250.
  • Culp, Inc. CULP declined 15.3% to $4.26 following Q4 results.
  • NextPlay Technologies, Inc. NXTP dropped 14.7% to $0.3350. NextPlay's In-Game Advertising unit, Hotplay entered into memorandum of understanding with Triplecom Media PVT.
  • Avenue Therapeutics, Inc. ATXI declined 14.4% to $0.2770.
  • Evofem Biosciences, Inc. EVFM fell 14.3% to $0.8403. Evofem Biosciences recently announced an agreement with a pharmacy benefit manager.
  • Verrica Pharmaceuticals Inc. VRCA dropped 14.1% to $1.8650 as the company reported pricing of public offering of common stock.
  • Can-Fite BioPharma Ltd. CANF fell 13.8% to $0.8795. Can-Fite BioPharma shares jumped over 15% on Wednesday after the company announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis.
  • Studio City International Holdings Limited MSC dropped 13.8% to $1.87.
  • Lexicon Pharmaceuticals, Inc. LXRX declined 13% to $1.95. Lexicon Pharmaceuticals reported positive topline results from the Phase 2 proof-of-concept study of its lead candidate LX9211 in painful diabetic neuropathy.
  • Cooper-Standard Holdings Inc. CPS fell 12.8% to $4.72.
  • Connect Biopharma Holdings Limited CNTB shares fell 12.2% to $0.87 after gaining around 9% on Wednesday.
  • Icosavax, Inc. ICVX dropped 11.4% to $6.21. Icosavax recently announced interim results from its Phase 1/1b clinical trial of its IVX-121 RSV F antigen in young and older adults.
  • Femasys Inc. FEMY fell 11.2% to $2.45 after gaining around 7% on Wednesday.
  • Journey Medical Corporation DERM dropped 9.4% to $3.37.
  • Adagene Inc. ADAG fell 9.1% to $1.89 after the company reported authorization of $10 million buyback program.
  • The Simply Good Foods Company SMPL dropped 8.5% to $37.69 folloiwng Q3 results.
  • First Wave BioPharma, Inc. FWBI shares fell 7.6% to $0.2958.
  • Q&K International Group Limited QK dropped 7.2% to $1.67.


Posted In: BiotechnologyCommunications EquipmentHealth CareInformation TechnologyMid-Day MoversTop GainersNewsPenny StocksSmall CapIntraday UpdateMarketsMoversTrading Ideas

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.